EGFR and non-small cell lung carcinoma: EGFR mutations are the most common driver gene mutations in lung cancer among Asian populations and directly affect treatment choice.1, 2, 3, 4, 5 EGFR tyrosine kinase inhibitors (TKIs) targeting these genes represent key drugs for EGFR-mutated advanced NSCLC.6, 7, 8, 9 First- (gefitinib and erlotinib), second- (afatinib and dacomitinib), and third-generation (osimertinib) EGFR TKIs are options for first-line treatment.10